Early trial tests novel combo for aggressive lymphomas that resist treatment
NCT ID NCT05371054
Summary
This early-stage study tested the safety and effectiveness of a new three-drug combination (VVIP) for adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The goal was to find the highest safe dose and see if the treatment could make the cancer disappear completely. Only 8 people participated in this small, completed Phase 1/2 trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.